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OBJECTIVEdTo add to the evidence on comparative long-term effects of insulin analog
glargine versus human NPH insulin on the risk for cancer.
RESEARCH DESIGN AND METHODSdWe identiﬁed cohorts of initiators of glargine
and human NPH without an insulin prescription during the prior 19 months among patients
covered by the Inovalon Medical Outcomes Research for Effectiveness and Economics Registry
(MORE
2 Registry) between January 2003 and December 2010. Patients were required to have a
second prescription of the same insulin within 180 days and to be free of cancer. We balanced
cohorts on risk factors for cancer outcomes based on comorbidities, comedication, and health
care use during the prior 12 months using inverse probability of treatment weighting. Incident
cancer was deﬁned as having two claims for cancer (any cancer) or the same cancer (breast,
prostate, colon) within 2 months. We estimated adjusted hazard ratios (HRs) and their 95% CI
using weighted Coxmodelscensoringfor stopping,switching,or augmentinginsulin treatment,
end of enrollment, and mortality.
RESULTSdMore patients initiated glargine (43,306) than NPH (9,147). Initiators of glargine
(NPH)werefollowedfor1.2(1.1)yearsand50,548(10,011)person-years;993(178)developed
cancer. The overall HR was 1.12 (95% CI 0.95–1.32). Results were consistent for breast cancer,
prostate cancer, and colon cancer; various durations of treatment; and sensitivity analyses.
CONCLUSIONSdPatientsinitiatinginsulinglargineratherthanNPHdonotseemtobeatan
increasedriskfor cancer.While our studycontributessigniﬁcantlytoourevidencebasefor long-
termeffects,thisevidenceisverylimitedmainlybasedonactualdynamicsininsulinprescribing.
Diabetes Care 36:3517–3525, 2013
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n June 2009, multiple research reports
addressed thepossibility of association
between the use of the long-acting
insulin analog glargine (Lantus) and can-
cer (1–4). This relation was examined be-
causeofinvitroobservationsthatglargine
is more mitogenic than human insulin;
subsequent studies have demonstrated
that the in vivo metabolite, which is the
dominant circulating form of glargine, is
not mitogenic in vitro (5,6). In the origi-
nalpublicationsaswellasfurtheranalyses
from additional datasets, results have
been quite heterogeneous, perhaps re-
lated to methodological differences (7–
17). The lack of consistent relations with
speciﬁc cancers has reduced anxiety re-
garding the potential effect of glargine
on cancer. Residual concerns focus on
breast cancer, particularly with longer ex-
posure, based on more frequent and
stronger associations as well as a general
lackofsubstantialdatainthatregard(10–
12,16). Because glargine is the most com-
monly prescribed formulation of insulin,
its safety is an issue of great clinical and
public health interest.
There is a clear association between
diabetes and cancer incidence and mor-
tality. The potential drivers of this asso-
ciation are incompletely understood but
include insulin resistance and obesity,
shared risk factors such as age and smok-
ing, health care system use (i.e., those
who are diagnosed with one condition
m a yb em o r el i k e l yt ob es c r e e n e df o rt h e
other condition), and medication expo-
sure (18,19). Despite the increased inci-
dence of cancer in those with diabetes,
cancer events in clinical trials are infre-
quent. Both a meta-analysis of the glar-
gine clinical trials program and the
results of two large safety studies with
5–7y e a r s ’ follow-up failed to demon-
strate any increased risk of cancer or can-
cer mortality; however, the total number
of events in these studies are modest and
thus too small to rule out clinically rele-
vant increases in risk, speciﬁcally for
breastcancerinwomen(20–22).Addition-
ally, though the Outcome Reduction With
Initial Glargine Intervention (ORIGIN)
trial reported .75,000 patient-years of
follow-up,itexcludedpatientswhowould
meet general indications for insulin ther-
apy. This may limit the generalizability of
its conclusions regarding glargine’s safety
(22).
Therefore,despitetherecentboomin
studies exploring glargine cancer associ-
ations, there is still a need for large
pharmacoepidemiologic studies that allow
better control for potential confounders as
well as analysis of induction periods;
namely, how the duration of treatment
ccccccccccccccccccccccccccccccccccccccccccccccccc
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ORIGINAL ARTICLEaffectstheriskobserved.Thiscanonlybe
accomplished with a clear time line for
the analysis; arguably, the best time line
starts with the initiation of insulin ther-
apy (23). We report the largest study to
datethataddressestheseimportantissues
for what we believe to be the most rele-
vant question raised by the June 2009
publications: In patients with diabetes
who are initiating treatment with long-
acting insulins, how does cancer incidence





METHODSdThe study was reviewed
and determined to be exempt from fur-
ther review by the University of North
Carolina at Chapel Hill Institutional Re-
view Board. The study protocol was
registered in the European Network of
Centres for Pharmacoepidemiology and
Pharmacovigilance (ENCePP) electronic




all patients with at least one diagnostic
code for diabetes (ICD-9-CM 250.XX)
enrolled in a U.S. health plan covered by
the Inovalon Medical Outcomes Research
for Effectiveness and Economics Registry
(MORE
2 Registry) (Bowie, MD) any time
between 1 January 2003 and 31 Decem-
ber 2010. The MORE
2 Registry contains
data for .76 million patients, 295,000
physicians, and 185,000 clinical facilities
and is often able to track patients who
change health plans (24). The MORE
2
Registry is comprised of all inpatient and
outpatient claims, dispensed prescription
medication claims, and mortality data
from the Social Security Administration’s
Death Master File.
We identiﬁed the ﬁrst (if any) dis-
pensed prescription for human NPH or a
premixed formulation of human NPH
and regular insulin (hereafter collectively
referred to as “NPH”) or analog insulin
glargineafter1July2004(Supplementary
Fig. 1)dthe index prescription. We then
excludedpatientswithoutcontinuousen-
rollment for 19 months prior to the index
prescription, deﬁned as having a claim
for any medication during each of four
6-month periods prior to the index pre-
scription.Withinthispopulationwithac-
tive use of drug insurance, we then
excluded patients with any dispensed
insulin prescriptions in the 19 months
prior to the index prescription with the
exception of a single prescription for
short-acting insulin (animal or human
regular insulin or rapid-acting analog in-
sulin). The 19-month period was chosen
to represent a usual 30-day supply plus a
grace period of 6 months plus a washout
period of 12 months.
From our cohort of initiators of long-
acting insulin (glargine or NPH), we
excluded patients with any evidence of
cancerorcancer-relatedprocedures(Sup-
plementary Table 1). This deﬁnition was
chosen to be as sensitive as possible with-
outimplyingspeciﬁcity(i.e.,erringonthe
side of excluding some patients that may
not have cancer). We then excluded pa-
tients younger than 18 years old at the
index prescription.
To increase the likelihood that dis-
pensed insulin was actually used by pa-
tients included in the cohort, we further
restricted our cohorts to patients with a
second prescription for the same insulin
(glargine or NPH) dispensed within 6
months after the index prescription. Fi-
nally, we excluded patients with any
evidence of cancer between the index
prescription and the second prescription.
Covariates and control for
confounding
All covariates were assessed during the
12 months prior to the index prescrip-
tion, and all analyses were controlled
forawidevarietyofvariables,including
calendar year of initiation, age, comor-
bidity, number of physician visits, number
of hospitalizations, various screenings
(mammography, prostate speciﬁca n t i -
gen, endoscopy), and medications. For a
completelistofvariables,seeTable1.Us-
ing these variables, we predicted the pro-
pensity for initiating glargine versus
initiating NPH for each patient based on
observed covariates (the propensity
score) (25). We then created pseudopop-
ulations, weighting each patient’sc o n -
tribution by the inverse probability of
receiving the treatment actually received,
i.e., inverse probability of treatment
weights (IPTW) (26). After checking the
maximum weight (7.722) and that the
mean weight was close to 1.0 (1.003),
which limits the potential for inﬂuential
patients to bias results, we assessed the
balance of observed covariates across
treatment cohorts in the pseudopopula-
tions (27). To avoid treatment compari-
sons outside a common range of the
propensity score (and thus possibly
covariates), we excluded patients initiat-
ing glargine with a propensity score
higher than the highest one observed in
patients initiating NPH and vice versa.
Cancer incidence
The cancer end points of interest were
breast,prostate,colon,and“any”(exclud-
ing nonmelanoma skin cancers). These
end points were considered separately
and deﬁned based on having at least two
codes for a speciﬁc cancer within 2
months (28). Breast cancer was deﬁned
as a primary or secondary diagnosis
(ICD-9-CM 174.X or 233.0); prostate
cancer (ICD-9-CM 185.X) and colon
cancer (ICD-9-CM 153.X) were deﬁned
accordingly. Codes used to deﬁne “any
cancer” are included in Supplementary
Table 2.
Patientsaccruedperson-timeoffollow-
up starting from the second prescription
until they stopped using the drug (no new
prescription for glargine or NPH, respec-
tively,withintherecordednumberofdays’
supply plus a 180-day grace period to al-
low for dose adjustment and irregular
use), ﬁlled a prescription for another
long-acting insulin (all patients were al-
lowedtoaugmentwithshort-actinginsu-
lin),died,orendedenrollment;thestudy
period ended (31 December 2010); or
they had a claim for any incident cancer
(exceptnonmelanomaskincancer).After
checking the proportional hazards as-
sumption by adding an interaction term
between (log) time and treatment, we
thenﬁtCoxproportionalhazardsmodels
for the various cancer outcomes in the
weighted pseudopopulations without
controlling for covariates (potentially af-
fected by treatment).
Sensitivity analyses
BMI is associated with an increased risk
of some cancers including colon and
postmenopausal breast but not prostate
cancer (29) and could confound the asso-
ciation between glargine versus NPH ini-
tiation and cancer incidenceif BMI would
affect the choice between initiating these
twotreatments.Totestthispossibility,we
estimated the association between BMI
and choice between initiating glargine
versus NPH independent of other covari-
ates, ﬁt t i n gp r o p e n s i t ys c o r em o d e l s
equivalent to the one in the main cohort
but using two electronic medical record
(EMR) databases where information on
BMI is available. We used EMR data
from the Massachusetts General Hospital
(MGH) and from Ochsner. Initiation of
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databases was deﬁned as for the Inovalon
database; however, only one prescription
record from the EMR was required to de-
ﬁne initiation, as these databases do not
contain a record for dispensing.
Additional sensitivity analyses were
performed to enhance the probability of
having type 2 diabetes (by restricting
cohorts to those .40 years of age and
with prior use of oral antihyperglycemic
agents), varying induction periods (ex-
cludingpatientswithearlycancerdiagno-
sis), varying carryover effects, and
excludingincreasingproportions ofthose
treated contrary to prediction (i.e., to as-
sess the potential for bias assuming un-
measured confounding [30]).
RESULTSdWe present the baseline
distribution of covariates in the two co-
horts of glargine initiators and NPH ini-
tiators in Table 1. Our cohort of patients
being initiated on glargine is slightly
older, more likely to be male, and more
likely to initiate treatment after 2008 than
patients initiating NPH (ﬁrst two col-
umns). The main differences between
the treatment cohorts are observed for
medication use at baseline. Patients initi-
atingglarginearemorelikelytohaveﬁlled
prescriptionsofantihypertensive,antihy-
perglycemic, and lipid-lowering drugs.
In contrast, patients initiating NPH are
more likely to have ﬁlled prescriptions
for estrogens and progestins. The preva-
lence of comorbidities is very similar in
both cohorts, as is health care use. Pa-
tients initiating glargine are more likely
to have had a cancer-screening test per-
formed in the year prior to baseline than
patients initiating NPH. In the third col-
umn, we present the multivariable effect
of these covariates on channeling be-
tween initiating glargine and NPH (i.e.,
resultsfromthepropensityscoremodel).
The virtually identical distribution of
the covariates in the propensity score
weighted pseudopopulation (last two
columns)provesthatwewereabletobal-
ance cohorts on all measured covariates,
thus eliminating confounding by these
covariates.
In Table 2, we present rates per
100,000 person-years and the crude and
adjusted hazard ratios (HRs) for incident
cancer for breast cancer (women only),
prostate cancer (men only), colon cancer,
and “any cancer.” All numbers are based
on our primary analysis, i.e., as treated,
where patients stopping, switching, or
augmenting their corresponding baseline
treatment are censored at that point in
time. The median duration of follow-up
in this analysis is 0.9 years in the glargine
cohort and 0.8 years in the NPH cohort.
The breast cancer analysis, based on
22,936 patients initiating glargine and
5,536 patients initiating NPH and 122
incident breast cancers, reveals an ad-
justed HR of 1.07 (95% CI 0.65–1.75).
ThecorrespondingHRforprostatecancer
(1.19 [0.73–1.94]), colon cancer (0.89
[0.49–1.60]), and any cancer (1.12
[0.95–1.32]) are all close to 1, indicating
no increased risk for cancer in glargine
initiators compared with NPH initiators.
We then stratiﬁed the analysis pre-
sented in Table 2 by duration of use since
initiation(Table3).Giventhemediandu-
rationoftreatmentpresentedabove,there
are sparse data for the .24-month strata,
especially for the NPH cohort. Based on
only 3,415 person-years and 14 incident
breastcancers,wefoundnoindicationfor
an increased risk for breast cancer in the
few women using glargine orNPH for .2
years (HR 0.67 [0.18–2.54]). The corre-
sponding HRs for the other cancer out-
comes are all close to 1.0, with the
exception of .12–24 months and pros-
tate cancer (2.66 [0.65–10.9]). This out-
lier result should be interpreted taking
into account the absence of a monotonic
pattern over duration of use and the
small number and the unusually low in-
cidencerateofprostatecancerintheNPH
cohort.
In Table 4, we present the results of
our two external validation studies to as-
sess the role of various covariates not
availableinclaimsdata.Inbothvalidation
studies,BMIdoesnotinﬂuencethechoice
between initiating long-acting insulin
therapy with glargine versus NPH. These
results were unaffected by controlling for
other covariates in the propensity score
model. The corresponding adjusted
odds ratios for BMI (1-unit increase) and
initiating glargine versus NPH were 1.00
(0.98–1.02) in the MGH cohort and 0.99
(0.96–1.03) in the Ochsner cohort.
All results were consistent when we
restricted the patient population to those
.40 years old and with prior use of oral
antihyperglycemic agents (i.e., limited to
patients with a very high probability of
having type 2 diabetes), varied induction
periods (i.e., excluding incident cancer
cases for up to 12 month after insulin ini-
tiation), varied carryover effects (i.e., al-
lowing for effects to carry on for up to 24
months or indeﬁnitely after stopping
treatment [ﬁrst treatment carried forward
or intention-to-treat analysis]), and ex-
cluded increasing proportions of those
treated contrary to prediction (i.e., to as-
sess the potential for bias assuming un-
measured confounding) (data not
presented). For example, the following
H R sw e r eo b s e r v e di nt h ei n t e n t i o n - t o -
treat analysis: 1.30 for breast cancer
(0.83–2.05), 1.21 for prostate cancer
(0.80–1.84), 0.97 for colon cancer (0.58–
1.63),and1.09foranycancer(0.95–1.25).
CONCLUSIONSdIn our large, new
user, active comparator cohort study, we
found no evidence that initiating patients
with diabetes with insulin glargine leads
to a higher risk of cancer compared with
initiating similar patients on NPH. This
result was consistent for overall and spe-
ciﬁc cancers (breast, prostate, colon)
and a variety of sensitivity analyses ad-
dressing the relation of timing of insulin
initiation with the risk for cancer (time
after initiation, induction periods, lag
times), subgroups, and the potential for
unmeasured confounding by BMI and
severity of diabetes.
A recent meta-analysis reported that
there was no difference in the rates of
breastcancerincidenceinpatientstreated
with insulin glargine compared with
other formulations of insulin, but there
was evidence for heterogeneity across
studies (31). There are several studies
that have suggested an increased risk of
breast cancer (10–12,16). In particular,
in a cohort of 15,227 women with type
2 diabetes followed for up to 8 years,
breast cancer risk was not increased dur-
ing the ﬁrst 5 years of glargine use but
there was a suggestion of increased risk
among those with .5 years exposure
(HR 1.8 [95% CI 0.8–40]). There was in-
sufﬁcient exposure among new users to
examine those with $5 years of treat-
ment. The results of two collaborating
groups from Northern Europe and Kaiser
Permanente were recently reported at
72nd Scientiﬁc Sessions of the American
Diabetes Association, Philadelphia,
Pennsylvania, 8–12 June 2012 (http://www
.diabetes.org/for-media/2012/sci-sessions-
insulin-cancer.html). Both studies reported
an increased HR for breast cancer in the
new user cohort with longer duration of
treatment. Our study has the largest co-
hort of new users of glargine reported to
date. The lack of an association among
new users of glargine compared with
new users of NPH for breast cancer, in-
cludingthosewithtreatmentover2years,
is reassuring, but further study of breast
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St€ urmer and AssociatesTable 1dDistribution of selected baseline characteristics in initiators of glargine and initiators of NPH and their effect on choice
between initiating glargine versus NPH*
Actual cohorts Effect on channeling,
OR (95% CI)†
Weighted cohorts (%)‡
Glargine NPH Glargine NPH
n 43,306 9,147
Age (years), mean (SD) 61.3 (14.0) 58.9 (17.2) 1.001 (0.999–1.003) 61.0 (14.3) 61.5 (15.5)
Sex
Male 20,369 (47.0) 3,611 (39.5) 1.29 (1.22–1.37) 45.8 45.7
Female 22,937 (53.0) 5,536 (60.5) 1.00 (reference) 54.2 54.3
Cohort year
2004 528 (1.2) 362 (4.0) 0.29 (0.25–0.34) 1.7 1.7
2005 1,558 (3.6) 662 (7.2) 0.48 (0.43–0.53) 4.3 4.2
2006 2,435 (5.6) 948 (10.4) 0.56 (0.51–0.62) 6.4 6.3
2007 5,984 (13.8) 1,395 (15.3) 0.88 (0.82–0.95) 14.1 13.9
2008 12,640 (29.2) 2,685 (29.4) 1.00 (reference) 29.2 28.7
2009 12,109 (28.0) 1,925 (21.1) 1.28 (1.20–1.37) 26.8 27.5
2010 8,052 (18.6) 1,170 (12.8) 1.42 (1.31–1.53) 17.6 17.7
Medications
ACE inhibitors 18,773 (43.4) 3,498 (38.2) 0.94 (0.89–0.99) 42.5 43.6
Anticholinergics 713 (1.7) 156 (1.7) 0.93 (0.77–1.13) 1.7 1.6
Antidepressants 11,028 (25.5) 2,062 (22.5) 1.18 (1.12–1.25) 25.0 26.4
ARBs 5,656 (13.1) 851 (9.3) 1.16 (1.07–1.26) 12.4 12.8
b-Blockers 15,678 (36.2) 2,842 (31.1) 0.98 (0.93–1.04) 35.4 36.6
b2-agonists 4,559 (10.5) 984 (10.8) 0.98 (0.90–1.07) 10.6 11.1
Bile acid sequestrants 237 (0.6) 43 (0.5) 1.01 (0.72–1.41) 0.5 0.5
Calcium channel blockers 9,813 (22.7) 1,826 (20.0) 0.97 (0.92–1.04) 22.2 23.2
Cholesterol absorption inhibitors 1,454 (3.4) 190 (2.1) 1.26 (1.07–1.47) 3.1 3.5
Digoxin 1,978 (4.6) 334 (3.7) 1.18 (1.04–1.34) 4.4 4.8
Estrogen 904 (2.1) 346 (3.8) 0.96 (0.79–1.16) 2.4 2.3
Fibrates 4,238 (9.8) 707 (7.7) 0.98 (0.89–1.06) 9.4 9.5
Loop diuretics 8,722 (20.1) 1,690 (18.5) 0.96 (0.89–1.03) 19.9 21.5
Metformin 27,347 (63.2) 4,544 (49.7) 1.26 (1.19–1.33) 60.8 61.2
Niacin 810 (1.9) 108 (1.2) 1.14 (0.93–1.41) 1.8 1.7
Nonloop diuretics 7,684 (17.7) 1,397 (15.3) 1.04 (0.97–1.11) 17.4 18.2
Oral contraceptives 593 (1.4) 317 (3.5) 0.71 (0.56–0.90) 1.7 1.6
Other diabetes drugs 9,416 (21.7) 891 (9.7) 1.87 (1.73–2.01) 19.7 21.4
Progestins 407 (0.9) 145 (1.6) 1.13 (0.89–1.45) 1.0 1.0
Statins 23,874 (55.1) 3,792 (41.5) 1.17 (1.11–1.23) 52.8 54.0
Sulfonylureas 28,399 (65.6) 4,443 (48.6) 1.57 (1.49–1.65) 62.7 64.4
Testosterone 250 (0.6) 30 (0.3) 1.42 (0.96–2.11) 0.5 0.6
Theophyline 275 (0.6) 44 (0.5) 1.39 (1.00–1.94) 0.6 0.7
Thiazolidinediones 14,085 (32.5) 1,954 (21.4) 1.46 (1.38–1.55) 30.6 31.8
Comorbidities
Congestive heart failure 8,074 (18.6) 1,645 (18.0) 1.01 (0.93–1.09) 18.6 19.6
Diabetic nephropathy 11,432 (26.4) 2,345 (25.6) 0.90 (0.84–0.95) 26.3 27.6
Diabetic neuropathy 9,998 (23.1) 2,110 (23.1) 0.86 (0.81–0.91) 23.1 23.7
Diabetic retinopathy 11,613 (26.8) 2,364 (25.8) 0.94 (0.89–1.00) 26.7 26.8
Hypertension 35,314 (81.6) 6,842 (74.8) 1.13 (1.06–1.20) 80.5 81.7
Pulmonary infection 10,642 (24.6) 2,344 (25.6) 0.98 (0.92–1.05) 24.8 25.9
Health care use
Hospitalizations (any reason)
1 8,961 (20.7) 1,922 (21.0) 1.17 (1.07–1.29) 20.8 21.9
2 3,144 (7.3) 662 (7.2) 1.15 (1.03–1.28) 7.3 7.6
$3 2,512 (5.8) 515 (5.6) 1.25 (1.11–1.42) 5.8 6.5
Days in hospital (any reason)
1–2 2,794 (6.5) 618 (6.8) 0.92 (0.82–1.04) 6.5 6.6
3–5 4,251 (9.8) 913 (10.0) 0.95 (0.86–1.06) 9.9 10.3
Continued on p. 3521
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Long-acting insulin and cancer: new user studycancer risk with long-standing glargine
use is necessary.
We used duration of treatment as a
proxy for cumulative dose. We could
have used a measure of cumulative dose
insteadbut,basedonthesmallnumberof
NPH initiators and the potential for time-
varying confounding, opted to focus on
the duration of treatment irrespective of
dose analysis.
We combined the new user design
with an active comparator cohort. Rather
than comparing treated with untreated,
this design allowed us to address a clin-
ically more important question: If I need
to initiate insulin therapy in my patients
with diabetes, does choosing insulin
glargine over NPH increase the risk for
cancer? Results of studies using active
comparators, while answering clinically
more important questions, are inherently
dependent on the comparator chosen.
We chose NPH insulin as a comparator
because 1) most guidelines provide NPH
insulin as the alternative to long-acting
basal analog insulins like glargine and 2)
there is insufﬁcient exposure to other
long-acting analog insulins in the U.S.
Compared with patients initiating
NPH, patients initiating glargine were
Table 1dContinued
Actual cohorts Effect on channeling,
OR (95% CI)†
Weighted cohorts (%)‡
Glargine NPH Glargine NPH
Physician encounters
1–3 6,014 (13.9) 1,368 (15.0) 1.01 (0.88–1.15) 14.1 14.0
4–6 9,429 (21.8) 1,934 (21.1) 0.96 (0.84–1.09) 21.7 21.3
$7 26,269 (60.7) 5,494 (60.1) 0.90 (0.79–1.02) 60.6 61.0
ED visits
1 9,017 (20.8) 1,965 (21.5) 0.94 (0.88–1.00) 21.0 21.8
2 3,819 (8.8) 810 (8.9) 1.00 (0.91–1.09) 8.8 9.4
$3 4,418 (10.2) 1,009 (11.0) 0.94 (0.86–1.04) 10.3 10.7
Screening tests
Prostate-speciﬁc antigen 7,862 (38.6) 1,274 (35.3) 0.97 (0.90–1.06) 38.1 37.6
Mammography 7,138 (31.1) 1,215 (22.0) 1.59 (1.47–1.72) 29.5 31.5
Endoscopy 3,843 (8.9) 694 (7.6) 1.07 (0.98–1.16) 8.7 9.3
PAP smear 4,410 (19.2) 1,617 (29.2) 0.55 (0.51–0.60) 21.0 19.2
Blood lipid 31,583 (72.9) 5,992 (78.8) 1.21 (1.15–1.28) 71.7 72.1
ECG 22,770 (52.6) 4,575 (50.0) 1.08 (1.02–1.14) 52.2 53.9
Data are n (%) unless otherwise indicated. ARB, angiotensin receptor blocker; ECG, electrocardiogram; ED, emergency department; OR, odds ratio. *Initiation
deﬁned as no dispensed prescriptions for insulin during the 19 months before the ﬁrst insulin prescription (with the exception of one prescription for a short-acting
insulin)andﬁllingasecondprescriptionofthesameinsulin(glargineorNPH)within6monthsaftertheﬁrstprescription.†Channelingbetweeninitiationofglargine
and initiation of NPH; ORs from multivariable logistic regression model including all covariates presented in the table (i.e., the propensity score model); ORs .1.0
indicate more likely to be initiated on glargine than NPH. ‡Pseudopopulation weighted by the IPTW to assess the performance of the propensity score to balance
covariates (and therefore control for confounding) in the pseudopopulation.
Table 2dInitiation of long-acting insulin treatment and cancer incidence*










Glargine 22,936 103 26,277 392 1.22 (0.75–2.00) 1.07 (0.65–1.75)
NPH 5,536 19 5,885 323 1.00 (reference) 1.00 (reference)
Prostate{
Glargine 20,298 119 24,208 494 1.02 (0.64–1.63) 1.19 (0.73–1.94)
NPH 3,602 20 4,116 486 1.00 (reference) 1.00 (reference)
Colon#
Glargine 43,290 62 50,530 123 0.77 (0.44–1.33) 0.89 (0.49–1.60)
NPH 9,145 16 10,010 160 1.00 (reference) 1.00 (reference)
Any cancer
Glargine 43,306 993 50,548 1,965 1.11 (0.95–1.30) 1.12 (0.95–1.32)
NPH 9,147 178 10,011 1,778 1.00 (reference) 1.00 (reference)
*Initiation deﬁned as no dispensed prescriptions for insulin during the 19 months before the ﬁrst insulin prescription (with the exception of one prescription for
ashort-actinginsulin)andﬁllingasecondprescriptionofthesameinsulin(glargineorNPH)within6monthsaftertheﬁrstprescription.†As-treatedanalysis:patients
stopping, switching, or augmenting their corresponding baseline treatment are censored at that point in time; median duration of follow-up 0.9 years in the glargine
cohort and 0.8 years in the NPH cohort. ‡HRs (95% CI) from Cox proportional hazards models for the various cancer outcomes with baseline treatment as the only
independentcovariate.xAdjustedforallvariablespresentedinTable1usingIPTW.||Womenonly;womenwithprophylacticunilateralorbilateralmastectomyatthe
index prescription excluded. {Men only; men with partial or complete prostatectomy for any reason at the index prescription excluded. #Patients with prophylactic
partial or complete removal of the colon at the index prescription excluded.
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Cancer, time stratum,










0t o,6m o n t h s
Glargine 22,936 37 9,552 387 1.27 (0.57–2.85) 0.99 (0.46–2.13)
NPH 5,536 7 2,296 305 1.00 (reference) 1.00 (reference)
6t o,12 months
Glargine 18,979 29 7,301 397 2.23 (0.68–7.33) 1.50 (0.52–4.31)
NPH 4,609 3 1,667 180 1.00 (reference) 1.00 (reference)
12 to ,24 months
Glargine 10,910 26 6,655 391 0.84 (0.35–2.04) 1.09 (0.38–3.12)
NPH 2,214 6 1,277 470 1.00 (reference) 1.00 (reference)
$24 months
Glargine 3,576 11 2,770 397 0.88 (0.24–3.27) 0.67 (0.18–2.54)
NPH 735 3 645 465 1.00 (reference) 1.00 (reference)
Prostate{
0t o,6m o n t h s
Glargine 20,298 45 8,531 528 0.98 (0.46–2.07) 1.07 (0.51–2.23)
NPH 3,602 8 1,468 545 1.00 (reference) 1.00 (reference)
6t o,12 months
Glargine 17,092 30 6,626 453 0.83 (0.35–2.00) 0.97 (0.41–2.31)
NPH 2,909 6 1,103 544 1.00 (reference) 1.00 (reference)
12 to ,24 months
Glargine 9,907 32 6,105 524 1.78 (0.54–5.80) 2.66 (0.65–10.9)
NPH 1,627 3 1,019 294 1.00 (reference) 1.00 (reference)
$24 months
Glargine 3,407 12 2,946 407 0.74 (0.22–2.48) 0.87 (0.21–3.65)
NPH 570 3 526 570 1.00 (reference) 1.00 (reference)
Colon#
0t o,6m o n t h s
Glargine 43,290 23 18,105 127 0.96 (0.37–2.53) 0.80 (0.33–1.95)
NPH 9,145 5 3,767 133 1.00 (reference) 1.00 (reference)
6t o,12 months
Glargine 36,113 17 13,940 122 0.69 (0.25–1.88) 0.90 (0.30–2.75)
NPH 7,525 5 2,773 180 1.00 (reference) 1.00 (reference)
12 to ,24 months
Glargine 20,834 16 12,769 125 0.58 (0.21–1.57) 1.03 (0.28–3.85)
NPH 3,846 5 2,298 218 1.00 (reference) 1.00 (reference)
$24 months
Glargine 6,987 6 5,716 105 1.18 (0.14–9.76) 0.92 (0.10–8.49)
NPH 1,306 1 1,172 85 1.00 (reference) 1.00 (reference)
Any cancer
0t o,6m o n t h s
Glargine 43,306 392 18,112 2,164 1.14 (0.88–1.46) 1.11 (0.86–1.42)
NPH 9,147 72 3,767 1,911 1.00 (reference) 1.00 (reference)
6t o,12 months
Glargine 36,125 259 13,945 1,857 1.04 (0.77–1.41) 1.14 (0.83–1.57)
NPH 7,526 50 2,774 1,803 1.00 (reference) 1.00 (reference)
12 to ,24 months
Glargine 20,842 242 12,773 1,895 1.12 (0.80–1.57) 1.06 (0.75–1.49)
NPH 3,846 39 2,298 1,697 1.00 (reference) 1.00 (reference)
$24 months
Glargine 6,989 100 5,718 1,749 1.21 (0.73–2.01) 1.34 (0.74–2.41)
NPH 1,306 17 1,172 1,451 1.00 (reference) 1.00 (reference)
*Initiation deﬁned as no dispensed prescriptions for insulin during the 19 months before the ﬁrst insulin prescription (with the exception of one prescription for
ashort-actinginsulin)andﬁllingasecondprescriptionofthesameinsulin(glargineorNPH)within6monthsaftertheﬁrstprescription.†As-treatedanalysis:patients
stopping, switching, or augmenting their corresponding baseline treatment are censored at that point in time; median duration of follow-up 0.9 years in the glargine
cohort and 0.8 years in the NPH cohort. ‡HRs (95% CI) from Cox proportional hazards models for the various cancer outcomes with baseline treatment as the only
independentcovariate.xAdjustedforallvariablespresentedinTable1usingIPTW.||Womenonly;womenwithprophylacticunilateralorbilateralmastectomyatthe
index prescription excluded. {Men only; men with partial or complete prostatectomy for any reason at the index prescription excluded. #Patients with prophylactic
partial or complete removal of the colon at the index prescription excluded.
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Long-acting insulin and cancer: new user studygenerally more likely to have ﬁlled pre-
scriptions for metformin, sulfonylureas,
thiazolidinediones, and other diabetes
drugs during the 12 months before initi-
ating insulin. Glargine initiators werealso
morelikelytohaveﬁlled prescriptions for
statins, have blood lipids tested, and have
had a mammography, suggesting that
glargine initiators are more likely to fol-
low guidelines of disease prevention, i.e.,
healthy users (32). We successfully bal-
anced the cohorts of glargine and NPH
initiators on all these factors using pro-
pensity scores.
Our study has to be interpreted in the
context of its limitations. While our study
contributes considerably to the evidence
base for longer-term treatment with glar-
gine, our data on treatment beyond 2
years are limited. This limitation was
mainly a function of patients not using
insulin glargine (or NPH) over prolonged
periods of time rather than lack of long-
term observation of patients. This high-
lights actual dynamics in the treatment of
patientswithinsulin.Ofnote,theseactual
dynamics also affect other studies, in-
cluding the Hemkens et al. (1) study that
reported an increase in cancer risk early
after initiation of glargine treatment, and
thus cannot explain the discrepancies in
results observed. While all patients in our
cohort initiated long-acting insulin after a
period of at least 19 months without insu-
lin use, some patients may have used insu-
lin prior to that period and then stopped.
We found ~100 out ofthe 52,453 patients
meeting new use criteria more than once,
indicating that new use equates to initia-
tion for the great majority of patients.
Whilehealthcareclaims data include pro-
spective,longitudinalrecords ofalmostall
dispensed prescriptions and are therefore
almost ideal to track drug exposures (32),
they are limited with respect to their sen-
sitivityand speciﬁcity todetectcancerand
capturing potentially important covari-
ates. We used an algorithm with high
speciﬁcity to deﬁne incident cancer (28)
because a high speciﬁcity limits bias of ra-
tio estimates (33).
Weusedtwoexternalvalidationstud-
ies to assess the potential for unmeasured
confoundingbyBMI(34)andcouldshow
that BMI does not affect the decision to
initiate insulin treatment with glargine
versus NPH. Given that we observed sim-
ilar patterns in two distinct settings, we
ﬁnd it plausible that this ﬁnding is gener-
alizable to our cohorts. We could not
control for a wide variety of other cova-
riates, including e.g., smoking and so-
cioeconomic status. While smoking
increases the risk for a widevariety of can-
cers, the potential for confounding by so-
cioeconomic status is limited because the
impact of income on cancer incidence is
c o m p l e xa n df a rf r o ms t r o n g .O u rd a t a
include a variety of different health care
plans with different copayment structures
that could inﬂuence channeling, but it is




sex, and various health care–seeking be-
haviors, e.g., screening examinations). To
assess the potential for socioeconomic
status affecting channeling, we stratiﬁed
our new usercohorts by Medicaid versus
commercially insured. Of all Medicaid
beneﬁciaries initiating insulin therapy
in 2010, 84.3% were initiated on glar-
gine; the corresponding number was
very similar (88.7%) in commercially in-
sured patients, further limiting the po-
tential for confounding. The number of
patients initiated on NPH was much
smallerthanthenumberinitiatedonglar-
gine in our study of U.S. patients with di-
abetes. While this reﬂects the reality of
most patients being initiated on glargine
rather than NPH in the U.S., it decreases
the precision of our estimates, especially
for long-term use. We therefore cannot
exclude chance as an alternative explana-
tion of our results.
Based on previous studies and the
substantial contribution of our study, we
conclude that there does not seem to be
an increased risk for cancer, including
breast cancer, after initiation of glargine
compared with NPH in patients with
(mostly type 2) diabetes. The current
evidence on long-term use is limited, how-
ever, mainly based on the actual dynamic
in insulin treatment in the “real world.”
While limiting our evidence base with re-
spect to risk for cancer, this relative lack
of empirically observed long-term use also
limits the hypothetical potential for nega-
tively affecting public health. As always,
physicians should weigh potential bene-
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2), mean 6 SD* 32.7 6 7.53 32.4 6 8.43
BMI (kg/m
2), n (%)
,19 4 (0.7) 8 (1.9)
19 to ,25 77 (13.4) 67 (16.3)
25 to ,30 150 (26.1) 105 (25.5)
30 to ,35 146 (25.4) 104 (25.2)
35 to ,40 114 (19.9) 64 (15.5)
40 to ,45 45 (7.8) 36 (8.7)




2), mean 6 SD 34.8 6 8.2 35.9 6 8.4
BMI (kg/m
2), n (%)
,19 2 (0.2) 0 (0.0)
19 to ,25 90 (7.8) 12 (9.4)
25 to ,30 267 (23.1) 19 (15.0)
30 to ,35 313 (27.1) 33 (26.0)
35 to ,40 239 (20.7) 27 (21.3)
40 to ,45 130 (11.3) 18 (14.2)
$45 114 (9.9) 18 (14.2)
*BMI calculated as weight in kilograms divided by the square of height in meters; according to WHO, a BMI
between 25 and 30 kg/m
2 is overweight and a BMI .30 kg/m
2 is obese.
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